Response deadline
Mon, Apr 27, 2026, 1:00 PM EDTSAM.gov listing
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Analyze This Opportunity in CaptureIQ
Compare your company's capabilities against this federal opportunity using CaptureIQ.
Opportunity details
- NAICS
- 325412
- Notice type
- Solicitation
- Original posted
- April 10, 2026
- Last updated
- October 19, 2026
- Notice ID
- 6a19c5ff9aca477db88d306836782c82
Summary
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed: a. Arynta - ADHD Agents - Stimulants b. Atmeksi - Skeletal Muscle Relaxants and Comb - NA c. Avtozma - TIBS - IL-1, IL-6, CTLA-4 d. Desmoda - Endocrine Agents Misc - NA e. Foundayo - Metabolic Dysfunction A - Weight Loss A f. Icotyde - TIBS -IL-23 g. Kygevvi - Metabolic Agents Misc - NA h. Lerochol - Antilipidemics-1 - PCSK-9 i. Loargys - Metabolic Agents-Misc - Replacement Enzyme j. Yuviwel - Growth Stimulating Agents - NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9203. Pre-quotation teleconference is on April 15, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Read Full Official Summary
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following May 2026 newly approved drugs will be reviewed: a. Arynta - ADHD Agents - Stimulants b. Atmeksi - Skeletal Muscle Relaxants and Comb - NA c. Avtozma - TIBS - IL-1, IL-6, CTLA-4 d. Desmoda - Endocrine Agents Misc - NA e. Foundayo - Metabolic Dysfunction A - Weight Loss A f. Icotyde - TIBS -IL-23 g. Kygevvi - Metabolic Agents Misc - NA h. Lerochol - Antilipidemics-1 - PCSK-9 i. Loargys - Metabolic Agents-Misc - Replacement Enzyme j. Yuviwel - Growth Stimulating Agents - NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9203. Pre-quotation teleconference is on April 15, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Related Federal Opportunities
Why this matters
- This notice is a solicitation.
- The listed response deadline is Apr 27, 2026.
- 2 related opportunities share this NAICS.
Related federal terms
Market context
4 Related OpportunitiesMatching opportunities on RFPCapture